Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al.
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
How next-generation sequencing will change the treatment of multiple myeloma
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
Gareth Morgan et al.